Inflammatix Secures $57M to Boost Infectious Disease Test

Inflammatix has successfully raised $57 million in new financing as it awaits FDA clearance for its TriVerity blood test, designed to rapidly diagnose bacterial and viral infections and assess sepsis risk in emergency rooms.

The current market for infectious disease diagnostics sees around 20 million emergency room visits annually due to acute infections. Sepsis remains a major concern in hospitals, both in terms of mortality and cost, particularly among care recipients. Inflammatix aims to transform this landscape with its blood test and Myrna instrument, which deliver results in about 30 minutes. Using artificial intelligence to analyse RNA segments, the test helps doctors make quicker, more informed decisions regarding antibiotic use and patient care.

Having completed technical development and received an FDA breakthrough designation, Inflammatix is positioning itself as a leader in rapid diagnostics. The new capital, led by Khosla Ventures and Think.Health, will help expand its team and fund essential studies.

With FDA approval estimated before the end of the year, Inflammatix is poised to revolutionize sepsis and infection care with its AI-powered TriVerity test. The company’s technology has the potential to significantly impact hospital protocols and patient outcomes.

For the latest updates and in-depth insights into the world of Medical Devices, including breakthrough treatments, industry trends, and regulatory news, contact Alex Martin today!